GENFIT Announces Publication of the 2023 Universal
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical ...
Read moreLille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical ...
Read moreLille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical ...
Read moreUS Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and ...
Read moreGENFIT highlighted new focus and development strategy in Acute On-Chronic Liver Failure (ACLF)ACLF is a very serious condition affecting ~294,0001 ...
Read moreGENFIT to lead 3 key events on ACLF during AASLD: ACLF Day for Investors/Analysts on November 11, 2023Patient Advocacy Council ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.